首页 > 最新文献

Indo Global Journal of Pharmaceutical Sciences最新文献

英文 中文
A Comparative Study between Aqueous and Ethanolic Extracts of Allium Odorum Linn with Reference to its Antioxidant and AlphaAmylase Inhibition Activities 香蒜水提液与醇提液抗氧化及α淀粉酶抑制活性的比较研究
Pub Date : 2021-01-01 DOI: 10.35652/igjps.2021.111008
N. Talukdar, R. Devi, Indrani Barman
{"title":"A Comparative Study between Aqueous and Ethanolic Extracts of Allium Odorum Linn with Reference to its Antioxidant and AlphaAmylase Inhibition Activities","authors":"N. Talukdar, R. Devi, Indrani Barman","doi":"10.35652/igjps.2021.111008","DOIUrl":"https://doi.org/10.35652/igjps.2021.111008","url":null,"abstract":"","PeriodicalId":13366,"journal":{"name":"Indo Global Journal of Pharmaceutical Sciences","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82480541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Solid Lipid Nanoparticles: A Review 固体脂质纳米颗粒:综述
Pub Date : 2021-01-01 DOI: 10.35652/igjps.2021.112004
M. Begum, N. B. Shaik
{"title":"Solid Lipid Nanoparticles: A Review","authors":"M. Begum, N. B. Shaik","doi":"10.35652/igjps.2021.112004","DOIUrl":"https://doi.org/10.35652/igjps.2021.112004","url":null,"abstract":"","PeriodicalId":13366,"journal":{"name":"Indo Global Journal of Pharmaceutical Sciences","volume":"81 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90970350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
From Conventional Treatment to Targeted Antimalarial Therapy: Building Up on Innovations 从常规治疗到靶向抗疟治疗:在创新的基础上建立
Pub Date : 2021-01-01 DOI: 10.35652/igjps.2021.111003
S. Akash, Gupta Pritee
: Despite many technological advancements and innovations, infectious disease like malaria continues to be one of the greatest health challenges worldwide. The conventional drug therapy has various limitations. There are various challenges faced by drug therapy and the eradication agenda. However, various new strategies are being investigated not only to treat the parasitic disease but to prevent its spread and relapse. Nanotechnology-based approaches (diagnosis treatment and prevention), reconsidering drugs with limitations, repurposing of drugs, and development of new drugs by modifying existing compounds, re-optimizing available antimalarial, creating new combinations, etc. are some of them. The use of herbal drugs for antimalarial therapy has provided a novel approach having lesser side effects, safety, and more efficacies. Recent developments like investigating new targets for antimalarial drugs, newer and more effective mechanisms for attacking the parasite, targeting organ system and multiple stages of the parasitic life cycle and many other newer approaches may revolutionize the way we are fighting the malaria parasite soon. © 2020 iGlobal Research and Publishing Foundation. All rights reserved.
*尽管有许多技术进步和创新,但疟疾等传染病仍然是全世界最大的健康挑战之一。传统的药物治疗有很多局限性。药物治疗和根除议程面临各种挑战。然而,人们正在研究各种新的策略,不仅是为了治疗这种寄生虫病,而且是为了防止它的传播和复发。其中一些是基于纳米技术的方法(诊断、治疗和预防)、重新考虑有局限性的药物、重新利用药物、通过修改现有化合物开发新药、重新优化现有抗疟药、创造新的组合等。使用草药进行抗疟治疗提供了一种副作用更小、更安全、更有效的新方法。最近的进展,如研究抗疟药物的新靶点,攻击寄生虫的更新和更有效的机制,针对器官系统和寄生虫生命周期的多个阶段,以及许多其他更新的方法,可能很快就会彻底改变我们对抗疟疾寄生虫的方式。©2020全球研究与出版基金会。版权所有。
{"title":"From Conventional Treatment to Targeted Antimalarial Therapy: Building Up on Innovations","authors":"S. Akash, Gupta Pritee","doi":"10.35652/igjps.2021.111003","DOIUrl":"https://doi.org/10.35652/igjps.2021.111003","url":null,"abstract":": Despite many technological advancements and innovations, infectious disease like malaria continues to be one of the greatest health challenges worldwide. The conventional drug therapy has various limitations. There are various challenges faced by drug therapy and the eradication agenda. However, various new strategies are being investigated not only to treat the parasitic disease but to prevent its spread and relapse. Nanotechnology-based approaches (diagnosis treatment and prevention), reconsidering drugs with limitations, repurposing of drugs, and development of new drugs by modifying existing compounds, re-optimizing available antimalarial, creating new combinations, etc. are some of them. The use of herbal drugs for antimalarial therapy has provided a novel approach having lesser side effects, safety, and more efficacies. Recent developments like investigating new targets for antimalarial drugs, newer and more effective mechanisms for attacking the parasite, targeting organ system and multiple stages of the parasitic life cycle and many other newer approaches may revolutionize the way we are fighting the malaria parasite soon. © 2020 iGlobal Research and Publishing Foundation. All rights reserved.","PeriodicalId":13366,"journal":{"name":"Indo Global Journal of Pharmaceutical Sciences","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82414072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Quantitative Analysis of Eugenol in Clove Extract and Nanoparticle Formulation by a Validated High-Performance Thin-layer Chromatographic Method 丁香提取物和纳米颗粒制剂中丁香酚的高效薄层色谱定量分析
Pub Date : 2021-01-01 DOI: 10.35652/igjps.2021.112006
Deepika Yadav, Shivansh Yadav, G. Jain, A. Mazumder, Roop k Khar
Eugenol (4-allyl-2-methoxyphenol) is the aromatic compound of the essential oil with the potential to modulate neuronal excitability. Nose to brain route of drug delivery via nanoparticle formulation has emerged as an alternative route drug delivery system for treatment of epilepsy. A selective and sensitive analytical method is required for evaluation of eugenol-based novel drug delivery systems. The objective of present study is to develop and validate a high-performance thin-layer chromatographic (HPTLC) method for the quantitative analysis of eugenol as bulk, in clove extract and in developed eugenol-loaded nanoparticle formulation. Chromatographic separation was achieved on silica gel pre-coated TLC aluminium plates 60F254, using methanol:distilled water (6:4, v/v) as the mobile phase. Quantitative analysis was carried out by densitometry at a wavelength of 280 nm. The method was validated as per ICH guidelines, to analyse eugenol in clove extract and to evaluate eugenol-loaded nanoparticles. Eugenol spots were observed at Rf value 0.58 ± 0.02. The detector response was linear (r = 0.9991) between 0.5 and 5.0 ng/spot. The intra- and inter-day precisions were 1.08–2.17 and 1.95-3.86 %, respectively. The limit of detection was 50 ng/spot and the limit of quantification was 150 ng/spot. The method proved to be simple, accurate, reproducible and rugged for eugenol. Evaluation of eugenol-loaded nanoparticle formulation demonstrated drug loading of 35.0%, encapsulation efficiency of 47.0% and sustained drug release following biphasic pattern. The present method is useful for the quantitative and qualitative analysis of eugenol and eugenol-loaded nanoparticle formulation. It provides significant advantages in terms of greater specificity and rapid analysis. © 2020 iGlobal Research and Publishing Foundation. All rights reserved.
丁香酚(4-烯丙基-2-甲氧基酚)是丁香精油的芳香化合物,具有调节神经元兴奋性的潜力。鼻到脑的纳米颗粒给药途径已成为治疗癫痫的另一种途径。需要一种选择性和敏感性的分析方法来评价基于丁香酚的新型给药系统。本研究的目的是建立并验证一种高效薄层色谱(HPTLC)方法,用于定量分析散装丁香酚,丁香提取物和开发的丁香酚负载纳米颗粒制剂。以甲醇:蒸馏水(6:4,v/v)为流动相,在60F254硅胶预涂TLC铝板上进行色谱分离。采用密度测定法在280 nm波长下进行定量分析。根据ICH指南验证了该方法,以分析丁香提取物中的丁香酚并评估丁香酚负载纳米颗粒。Rf值为0.58±0.02时可见丁香酚斑点。检测器响应在0.5 ~ 5.0 ng/spot之间呈线性关系(r = 0.9991)。日内、日间精密度分别为1.08 ~ 2.17%、1.95 ~ 3.86%。检测限为50 ng/spot,定量限为150 ng/spot。结果表明,该方法简便、准确、重现性好、稳定性好。评价结果表明,丁香酚载药纳米颗粒的载药量为35.0%,包封率为47.0%,缓释呈双相模式。该方法可用于丁香酚和丁香酚负载纳米颗粒制剂的定量和定性分析。它在更大的特异性和快速分析方面提供了显著的优势。©2020全球研究与出版基金会。版权所有。
{"title":"Quantitative Analysis of Eugenol in Clove Extract and Nanoparticle Formulation by a Validated High-Performance Thin-layer Chromatographic Method","authors":"Deepika Yadav, Shivansh Yadav, G. Jain, A. Mazumder, Roop k Khar","doi":"10.35652/igjps.2021.112006","DOIUrl":"https://doi.org/10.35652/igjps.2021.112006","url":null,"abstract":"Eugenol (4-allyl-2-methoxyphenol) is the aromatic compound of the essential oil with the potential to modulate neuronal excitability. Nose to brain route of drug delivery via nanoparticle formulation has emerged as an alternative route drug delivery system for treatment of epilepsy. A selective and sensitive analytical method is required for evaluation of eugenol-based novel drug delivery systems. The objective of present study is to develop and validate a high-performance thin-layer chromatographic (HPTLC) method for the quantitative analysis of eugenol as bulk, in clove extract and in developed eugenol-loaded nanoparticle formulation. Chromatographic separation was achieved on silica gel pre-coated TLC aluminium plates 60F254, using methanol:distilled water (6:4, v/v) as the mobile phase. Quantitative analysis was carried out by densitometry at a wavelength of 280 nm. The method was validated as per ICH guidelines, to analyse eugenol in clove extract and to evaluate eugenol-loaded nanoparticles. Eugenol spots were observed at Rf value 0.58 ± 0.02. The detector response was linear (r = 0.9991) between 0.5 and 5.0 ng/spot. The intra- and inter-day precisions were 1.08–2.17 and 1.95-3.86 %, respectively. The limit of detection was 50 ng/spot and the limit of quantification was 150 ng/spot. The method proved to be simple, accurate, reproducible and rugged for eugenol. Evaluation of eugenol-loaded nanoparticle formulation demonstrated drug loading of 35.0%, encapsulation efficiency of 47.0% and sustained drug release following biphasic pattern. The present method is useful for the quantitative and qualitative analysis of eugenol and eugenol-loaded nanoparticle formulation. It provides significant advantages in terms of greater specificity and rapid analysis. © 2020 iGlobal Research and Publishing Foundation. All rights reserved.","PeriodicalId":13366,"journal":{"name":"Indo Global Journal of Pharmaceutical Sciences","volume":"532 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80181769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review on Nanosponges- A Versatile Drug Delivery System 纳米海绵——一种多功能给药系统的研究进展
Pub Date : 2021-01-01 DOI: 10.35652/igjps.2021.111007
G. Harsha, N. B. Shaik
Target effective drug delivery systems are the novel approach for delivering various active moieties to targeted site. Targeting active moieties to a specific site is achieved by appropriate nanotechnology as targeted drug delivery system has various drawbacks. In order to combat this problem various dosage forms have been developed with nanotechnology among those the one with discrete functionalized particles are called as Nanosponges. Nanosponges are porous polymeric nanoparticles which are spherical in shape about a size of virus and can load wide variety of drugs. These nanoparticles with nanosize circulate rapidly in the body till they achieve specific target site and release drug in predictable and sustained manner. A detailed introduction about nanosponges and its various advantages when compared with vesicular systems, its mechanism of drug release, various drugs formulated as nanosponges, preparation and evaluations of nanosponges with applications in pharmacy are provided. This article provides a clear cut view of nanosponges and its targeted delivery, by which drugs with low solubility, bioavailability and adverse effects can easily formulated by overcoming all these problems. © 2020 iGlobal Research and Publishing Foundation. All rights reserved. Cite this article as: Harsha, G.; Shaik, N.B. Review on NanospongesA Versatile Drug Delivery System. Indo Global J. Pharm. Sci., 2021; 11(1): 47-55. DOI: http://doi.org/10.35652/IGJPS.2021.111007 . Indo Global Journal of Pharmaceutical Sciences, 2021; 11(1): 47-55 48 colloidal nature and reported to have high solubilization capacity of poorly water soluble drug which provide sustained release as well as improving drug bioavailability. Because of their inner hydrophobic and outer hydrophilic branching, they are able to load both hydrophilic and hydrophobic drug molecules offering unparalleled flexibility[4]. COMPOSITION AND STRUCTURE OF
靶向有效药物递送系统是一种将各种活性成分递送到目标部位的新方法。靶向药物递送系统存在各种缺陷,因此通过适当的纳米技术可以将活性部分靶向到特定位点。为了解决这一问题,人们利用纳米技术开发了各种剂型,其中具有离散功能化颗粒的剂型被称为纳米海绵。纳米海绵是多孔的聚合纳米颗粒,其形状与病毒大小相当,可以装载多种药物。这些纳米颗粒在体内快速循环,直到到达特定的靶点,并以可预测和持续的方式释放药物。本文详细介绍了纳米海绵及其与囊泡系统相比的各种优势、纳米海绵的药物释放机制、各种纳米海绵制剂、纳米海绵的制备和评价及其在药学上的应用。本文提供了纳米海绵及其靶向递送的清晰视角,通过克服这些问题,可以很容易地配制出低溶解性、低生物利用度和不良反应的药物。©2020全球研究与出版基金会。版权所有。引用本文如下:Harsha, G.;纳米海绵——一种多功能给药系统的研究进展。印度国际制药公司。科学。, 2021;11(1): 47-55。DOI: http://doi.org/10.35652/IGJPS.2021.111007。印度全球药物科学杂志,2021;11(1): 47-55 48胶体性质,据报道对水溶性差的药物具有高的增溶能力,提供缓释并提高药物的生物利用度。由于其内部疏水和外部亲水分支,它们能够装载亲水性和疏水性药物分子,具有无与伦比的灵活性[4]。的组成和结构
{"title":"Review on Nanosponges- A Versatile Drug Delivery System","authors":"G. Harsha, N. B. Shaik","doi":"10.35652/igjps.2021.111007","DOIUrl":"https://doi.org/10.35652/igjps.2021.111007","url":null,"abstract":"Target effective drug delivery systems are the novel approach for delivering various active moieties to targeted site. Targeting active moieties to a specific site is achieved by appropriate nanotechnology as targeted drug delivery system has various drawbacks. In order to combat this problem various dosage forms have been developed with nanotechnology among those the one with discrete functionalized particles are called as Nanosponges. Nanosponges are porous polymeric nanoparticles which are spherical in shape about a size of virus and can load wide variety of drugs. These nanoparticles with nanosize circulate rapidly in the body till they achieve specific target site and release drug in predictable and sustained manner. A detailed introduction about nanosponges and its various advantages when compared with vesicular systems, its mechanism of drug release, various drugs formulated as nanosponges, preparation and evaluations of nanosponges with applications in pharmacy are provided. This article provides a clear cut view of nanosponges and its targeted delivery, by which drugs with low solubility, bioavailability and adverse effects can easily formulated by overcoming all these problems. © 2020 iGlobal Research and Publishing Foundation. All rights reserved. Cite this article as: Harsha, G.; Shaik, N.B. Review on NanospongesA Versatile Drug Delivery System. Indo Global J. Pharm. Sci., 2021; 11(1): 47-55. DOI: http://doi.org/10.35652/IGJPS.2021.111007 . Indo Global Journal of Pharmaceutical Sciences, 2021; 11(1): 47-55 48 colloidal nature and reported to have high solubilization capacity of poorly water soluble drug which provide sustained release as well as improving drug bioavailability. Because of their inner hydrophobic and outer hydrophilic branching, they are able to load both hydrophilic and hydrophobic drug molecules offering unparalleled flexibility[4]. COMPOSITION AND STRUCTURE OF","PeriodicalId":13366,"journal":{"name":"Indo Global Journal of Pharmaceutical Sciences","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84278532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Review: p-Coumaric Acid, A Medicinally Important Phenolic Acid Moiety 对香豆酸是一种重要的药用酚酸片段
Pub Date : 2021-01-01 DOI: 10.35652/igjps.2021.112007
S. Sharma, A. Khatkar, S. Kakkar
p-Coumaric acid is an ubiquitous natural phenolic phytochemical mainly exist in two forms trans- and cis-p-coumaric acid. It occurs in free as well as in bound forms, is a common dietary polyphenol distributed in fruits, vegetables and cereals. It was considered as a powerful antioxidant and widely reported to demonstrate antimicrobial, antifungal, anticancer, antidiabetic, anti-inflammatory, antiviral, antihypertensive, antiulcer, antiprotozoal and antimelanogenic. This review contains the fundamental information about biological potential, common pathway utilized, SAR, wide source of p-coumaric acid and evidence of their role in disease prevention. © 2020 iGlobal Research and Publishing Foundation. All rights reserved.
对香豆酸是一种普遍存在的天然酚类植物化学物质,主要以反式和顺式对香豆酸两种形式存在。它以游离和结合的形式存在,是一种常见的膳食多酚,分布在水果、蔬菜和谷物中。它被认为是一种强大的抗氧化剂,并被广泛报道具有抗菌、抗真菌、抗癌、抗糖尿病、抗炎、抗病毒、抗高血压、抗溃疡、抗原虫和抗黑色素瘤的作用。本文综述了对香豆酸的生物学潜力、常用途径、SAR、广泛来源及其在疾病预防中的作用。©2020全球研究与出版基金会。版权所有。
{"title":"A Review: p-Coumaric Acid, A Medicinally Important Phenolic Acid Moiety","authors":"S. Sharma, A. Khatkar, S. Kakkar","doi":"10.35652/igjps.2021.112007","DOIUrl":"https://doi.org/10.35652/igjps.2021.112007","url":null,"abstract":"p-Coumaric acid is an ubiquitous natural phenolic phytochemical mainly exist in two forms trans- and cis-p-coumaric acid. It occurs in free as well as in bound forms, is a common dietary polyphenol distributed in fruits, vegetables and cereals. It was considered as a powerful antioxidant and widely reported to demonstrate antimicrobial, antifungal, anticancer, antidiabetic, anti-inflammatory, antiviral, antihypertensive, antiulcer, antiprotozoal and antimelanogenic. This review contains the fundamental information about biological potential, common pathway utilized, SAR, wide source of p-coumaric acid and evidence of their role in disease prevention. © 2020 iGlobal Research and Publishing Foundation. All rights reserved.","PeriodicalId":13366,"journal":{"name":"Indo Global Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78298578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and Validation of New Analytical RP-HPLC Method for the Estimation of Antidiabetic Drugs Metformin Hydrochloride and Ertugliflozin in Combined Pharmaceutical Dosage Form 反相高效液相色谱法测定降糖药盐酸二甲双胍和埃图格列净联合剂型的含量
Pub Date : 2021-01-01 DOI: 10.35652/igjps.2021.111009
Suleman S. Khoja, Laxmanbhai J. Patel
Metformin Hydrochloride and Ertugliflozin is combination of Antidiabetic drug in tablet Segluromet ® Tablet (500/7.5 mg), a member Antidiabetic drug, is a recent drug developed by Merck Sharp & Dohme Company for the treatment of Type 2 diabetes. A new sensitive and rapid HPLC method was developed for the determination of Metformin Hydrochloride and Ertugliflozin in pharmaceutical dosage forms; it was validated according to International Conference on Harmonization and Food and Drug Administration guidelines. The analysis was performed on the HPLC system equipped with a using Kromasil C18 (5 μm ), (250 mm x 4.6 mm column, with of Buffer (0.1 % v/v Phosphoric acid in water ) and Acetonitrile(ACN) in the ratio 60 : 40 v/v with at a flow rate of 1 mL/min , column temperature 25°C , total run time was 20 min, injection volume 20 μl, and detection was performed at the a wavelength (λ) of 235 nm. the calibration plot gave linear relationship over the concentration range of Metformin Hydrochloride 350, 450, 500, 550 and 600 μg/ml, and Ertugliflozin 6.80, 8.74, 9.72, 10.69 and 11.66 μg/ml, respectively. The accuracy of the proposed method was determined by recovery studies and was found to be Metformin Hydrochloride 98.5 % to 101.3 % and Ertugliflozin 98.2 % to 100.3%. The Limit of Detection were 0.0003 and 0.0009 μg/ml for Metformin Hydrochloride and Ertugliflozin, respectively and the Limit of Quantitation were 0.0037 and 0.0112 μg/ml for Metformin Hydrochloride and Ertugliflozin, respectively. % Relative Standard Deviation of the determination of precision was <2%. The results of robustness and solutions stability studies were within the acceptable limits as well the main features of the developed method are low run time and retention time of around 1.8 min for Metformin Hydrochloride (Met) and 3.8 min for Ertugliflozin (Ertu). © 2020 iGlobal Research and Publishing Foundation. All rights reserved. Cite this article as: Khoja, S.S.; Patel, L.J. Development and Validation of new analytical RP-HPLC method for the estimation of Antidiabetic Drugs Metformin hydrochloride and Ertugliflozin in combined pharmaceutical dosage form. Indo Global J. Pharm. Sci., 2021; 11(1): 62-69. DOI: http://doi.org/10.35652/IGJPS.2021.111009 . Indo Global Journal of Pharmaceutical Sciences, 2021; 11(1): 62-69 63 Figure. 1 Metformin Hydrochloride Ertugliflozin: Ertugliflozin is an oral, selective inhibitor of sodium glucose co-transporter-2 (SGLT2) which inhibits renal glucose reabsorption and results in urinary glucose excretion (UGE) and reductions in plasma glucose and haemoglobin A1c (Estimated Blood Sugar) in patients with type 2 diabetes mellitus (T2DM). It possesses a high selectivity for SGLT2 versus SGLT1 and other glucose transporters (GLUT1-4). Ertugliflozin is a new chemical entity with a chemical name of (1S,2S,3S,4R,5S)-5-[4-Chloro-3(4-ethoxybenzyl)phenyl]-1hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (Figure 2). Ertugliflozin is included in the drug pr
取埃图列净5 mg和盐酸二甲双胍标准品500 mg放入100ml容量瓶中,加入70 ml稀释剂和超声波溶解,冷却。用稀释液稀释至体积后混合。将5ml溶液转移到50ml容量瓶中,用稀释液稀释至体积,混合均匀。准确称量并将约595 mg合成混合物(相当于9.72 mg埃图格列净L-PGA(相当于7.5 mg埃图格列净)和500 mg盐酸二甲双胍标准品)转移到100 ml容瓶中,加入50 ml稀释剂,间歇摇晃,超声15分钟。用稀释液稀释至体积后混合。取部分溶液用0.45 μ PVDF注射器过滤器过滤,取5ml溶液放入50ml容量瓶中,用稀释液稀释至体积,混合均匀。方法按照ICH和FDA指南进行验证,验证参数包括特异性、线性度、范围、准确度、精密度、灵敏度(LOQ和LOD)、稳健性和溶液稳定性[5-7]。a)特异性:特异性是高效液相色谱法的重要特征之一,它是指分析方法区分分析物与复杂混合物中其他成分的能力。分别注射20 μL标准品溶液、样品溶液、空白溶液和安慰剂溶液,评价方法的特异性。b)线性度:为评价方法的线性度和范围,分别用不同浓度的盐酸二甲双胍稀释液(350、450、500、550、600 μg/ml)和埃图格列净(6.80、8.74、9.72、10.69、11.66 μg/ml)稀释标准原液制备直接标准溶液,分别占目标浓度的70%、90%、100%、110%、120%。在相同条件下分析每个浓度的三次重复注射。采用线性回归分析对2021年《印度全球药物科学杂志》进行评价;11(1): 62-69 64线性度的标定曲线采用最小二乘线性回归方法。c)灵敏度:通过测量信噪比确定盐酸二甲双胍和埃图格列净的检出限(LOD)/定量限(LOQ)。检测限(LOD)是指信噪比约为3:1的浓度,定量限(LOQ)是指信噪比约为10:1且%RSD (n = 3)小于10%的浓度。d)准确性:通过对盐酸二甲双胍、埃图格列净6.8、9.72、11.66 μg/ml分别为350、500、600 μg/ml三个浓度水平(70%、100%、120%)的回收率研究,确定测定方法的准确性,每个浓度注射3个样品。计算3个重复样品中盐酸二甲双胍和埃图格列净的添加回收率和RSD。e)精密度:所提方法的系统精密度和方法精密度(重复性)分别通过对标准溶液和样品溶液的多次测量来确定[7-9]。通过在同一天对100%浓度水平的标准溶液进行6次测量,建立了系统的精度。通过在同一天对样品溶液在100%浓度水平下进行6次测定来确定方法的精密度[9-12]。计算所得结果的RSD,评价结果的重复性。f)稳健性:通过对实验参数进行轻微和故意的改变来验证该方法的稳健性,例如:(i)柱温:±2°C (ii)流速:±0.2 mL/min。进行了更改以评估其对方法的影响。通过计算RSD %和恢复百分比对每个病例获得的数据进行评估。g)分析溶液的稳定性:在室温25℃条件下,分别在初始、12小时和24小时对标准品和样品进行分析,确定分析溶液的稳定性。对每种溶液的三次注射进行分析,计算峰的平均值和RSD。结果与讨论方法开发与优化从文献中得到了盐酸二甲双胍和埃图格列净的若干理化性质。建立了初步反相高效液相色谱法色谱条件的选择方法,包括检测波长、流动相、固定相、样品制备工艺等。为此,通过改变纳入试验的比例进行了一系列试验。表1。色谱柱流动相流速波长观察Kromasil C18 (5 μm) (250 mm × 4.6 mm)水:甲醇(60:40)1.0 ml/min 235 nm两种药物的峰形不一致Kromasil C18 (5 μm) (250 mm × 4.6 mm)水:甲醇(50:50) 两种药物Kromasil C18 (5 μm) (250 mm × 4.6 mm)峰形不一致
{"title":"Development and Validation of New Analytical RP-HPLC Method for the Estimation of Antidiabetic Drugs Metformin Hydrochloride and Ertugliflozin in Combined Pharmaceutical Dosage Form","authors":"Suleman S. Khoja, Laxmanbhai J. Patel","doi":"10.35652/igjps.2021.111009","DOIUrl":"https://doi.org/10.35652/igjps.2021.111009","url":null,"abstract":"Metformin Hydrochloride and Ertugliflozin is combination of Antidiabetic drug in tablet Segluromet ® Tablet (500/7.5 mg), a member Antidiabetic drug, is a recent drug developed by Merck Sharp & Dohme Company for the treatment of Type 2 diabetes. A new sensitive and rapid HPLC method was developed for the determination of Metformin Hydrochloride and Ertugliflozin in pharmaceutical dosage forms; it was validated according to International Conference on Harmonization and Food and Drug Administration guidelines. The analysis was performed on the HPLC system equipped with a using Kromasil C18 (5 μm ), (250 mm x 4.6 mm column, with of Buffer (0.1 % v/v Phosphoric acid in water ) and Acetonitrile(ACN) in the ratio 60 : 40 v/v with at a flow rate of 1 mL/min , column temperature 25°C , total run time was 20 min, injection volume 20 μl, and detection was performed at the a wavelength (λ) of 235 nm. the calibration plot gave linear relationship over the concentration range of Metformin Hydrochloride 350, 450, 500, 550 and 600 μg/ml, and Ertugliflozin 6.80, 8.74, 9.72, 10.69 and 11.66 μg/ml, respectively. The accuracy of the proposed method was determined by recovery studies and was found to be Metformin Hydrochloride 98.5 % to 101.3 % and Ertugliflozin 98.2 % to 100.3%. The Limit of Detection were 0.0003 and 0.0009 μg/ml for Metformin Hydrochloride and Ertugliflozin, respectively and the Limit of Quantitation were 0.0037 and 0.0112 μg/ml for Metformin Hydrochloride and Ertugliflozin, respectively. % Relative Standard Deviation of the determination of precision was <2%. The results of robustness and solutions stability studies were within the acceptable limits as well the main features of the developed method are low run time and retention time of around 1.8 min for Metformin Hydrochloride (Met) and 3.8 min for Ertugliflozin (Ertu). © 2020 iGlobal Research and Publishing Foundation. All rights reserved. Cite this article as: Khoja, S.S.; Patel, L.J. Development and Validation of new analytical RP-HPLC method for the estimation of Antidiabetic Drugs Metformin hydrochloride and Ertugliflozin in combined pharmaceutical dosage form. Indo Global J. Pharm. Sci., 2021; 11(1): 62-69. DOI: http://doi.org/10.35652/IGJPS.2021.111009 . Indo Global Journal of Pharmaceutical Sciences, 2021; 11(1): 62-69 63 Figure. 1 Metformin Hydrochloride Ertugliflozin: Ertugliflozin is an oral, selective inhibitor of sodium glucose co-transporter-2 (SGLT2) which inhibits renal glucose reabsorption and results in urinary glucose excretion (UGE) and reductions in plasma glucose and haemoglobin A1c (Estimated Blood Sugar) in patients with type 2 diabetes mellitus (T2DM). It possesses a high selectivity for SGLT2 versus SGLT1 and other glucose transporters (GLUT1-4). Ertugliflozin is a new chemical entity with a chemical name of (1S,2S,3S,4R,5S)-5-[4-Chloro-3(4-ethoxybenzyl)phenyl]-1hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (Figure 2). Ertugliflozin is included in the drug pr","PeriodicalId":13366,"journal":{"name":"Indo Global Journal of Pharmaceutical Sciences","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73897607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Novel Approach for Producing Pharmaceuticals in Layer by Layer Fashion: Additive Manufacturing 逐层生产药品的新方法:增材制造
Pub Date : 2021-01-01 DOI: 10.35652/igjps.2021.111010
Lakshmi Usha Ayalasomayajula, Kishore Pathivada, Radha Rani Earle, A. Bhavani
drug three ABSTRACT: A novel approach for producing pharmaceuticals from digital designs, in a layer-by-layer fashion is 3D printing. It has been acclaimed as a disruptive technology having the potential to make a paradigm shift in the conventional manufacturing of pharmaceuticals products which involves various unit operations like milling, mixing, granulation, drying and compression. It results in final products of different qualities. The quality of the product is influenced by loading of the drug, release of the drug, stability of the drug and stability of pharmaceutical dosage form. FDA approved 3D printed drug is creating a novel era in pharmaceutical manufacturing. To overcome some of the challenges associated with conventional pharmaceutical unit operations, 3D printing is gaining more attention in the manufacture of pharmaceuticals in the future. 3D printing is capable of overcoming the difficulties relating to the drug delivery of peptides, potent drugs, water-soluble drugs, and the release of multi-drugs. On the other hand we can prepare patient specific or patient tailored medications on patient demand thus making safe administration of drug without any side effects or adverse drug effects. Nevertheless,certain limitations are there in terms of regulatory aspects hindering the launch of 3DP products into the market. © 2020 iGlobal Research and Publishing Foundation.
摘要:3D打印是一种从数字设计中逐层生产药物的新方法。它被认为是一种颠覆性的技术,有可能使传统制药产品的制造发生范式转变,这涉及到各种单元操作,如碾磨、混合、造粒、干燥和压缩。它导致最终产品的质量不同。药物的载药量、药物的释放度、药物的稳定性和药物剂型的稳定性影响产品的质量。美国食品和药物管理局批准3D打印药物正在创造一个制药制造的新时代。为了克服与传统制药设备操作相关的一些挑战,3D打印在未来的制药制造中越来越受到关注。3D打印能够克服多肽、强效药物、水溶性药物的药物递送和多种药物的释放等困难。另一方面,我们可以根据患者的需求准备患者特定或量身定制的药物,从而使药物安全管理,没有任何副作用或药物不良反应。然而,在监管方面存在一定的限制,阻碍了3d打印产品进入市场。©2020全球研究与出版基金会。
{"title":"Novel Approach for Producing Pharmaceuticals in Layer by Layer Fashion: Additive Manufacturing","authors":"Lakshmi Usha Ayalasomayajula, Kishore Pathivada, Radha Rani Earle, A. Bhavani","doi":"10.35652/igjps.2021.111010","DOIUrl":"https://doi.org/10.35652/igjps.2021.111010","url":null,"abstract":"drug three ABSTRACT: A novel approach for producing pharmaceuticals from digital designs, in a layer-by-layer fashion is 3D printing. It has been acclaimed as a disruptive technology having the potential to make a paradigm shift in the conventional manufacturing of pharmaceuticals products which involves various unit operations like milling, mixing, granulation, drying and compression. It results in final products of different qualities. The quality of the product is influenced by loading of the drug, release of the drug, stability of the drug and stability of pharmaceutical dosage form. FDA approved 3D printed drug is creating a novel era in pharmaceutical manufacturing. To overcome some of the challenges associated with conventional pharmaceutical unit operations, 3D printing is gaining more attention in the manufacture of pharmaceuticals in the future. 3D printing is capable of overcoming the difficulties relating to the drug delivery of peptides, potent drugs, water-soluble drugs, and the release of multi-drugs. On the other hand we can prepare patient specific or patient tailored medications on patient demand thus making safe administration of drug without any side effects or adverse drug effects. Nevertheless,certain limitations are there in terms of regulatory aspects hindering the launch of 3DP products into the market. © 2020 iGlobal Research and Publishing Foundation.","PeriodicalId":13366,"journal":{"name":"Indo Global Journal of Pharmaceutical Sciences","volume":"76 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77392725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ayurveda in Management of Side Effects of Oncotherapy 阿育吠陀在肿瘤治疗副作用管理中的应用
Pub Date : 2021-01-01 DOI: 10.35652/igjps.2021.113003
S. Sarkar, Ananta Choudhury, B. Dey
Cancer, being a leading cause of death takes away approximately 9.6 million life per year globally. Drugs, chemotherapy and radiation therapies used for cancer treatment are often toxic and damages the adjacent healthy cells. The side effects may be acute (occurring within a few weeks after therapy), intermediate or late (occurring months or years after the therapy). The presently available “protectors” for overcoming the side effects of therapy have not been up to the mark which creates the need of finding a more efficient alternative. Ayurveda an ancient system of medicine and most widely practiced especially because of its side effects free treatment principles. According to Ayurveda, there are three ‘doshas’ (Vata, Pitta, and Kapha). The side effects of chemotherapy and radiotherapy are very common with the signs of aggravated ‘pitta dosha’. In Ayurveda, two ‘vishas’ (gara and dushivisha) are also there. Theses cause symptoms like chemotherapy and radiotherapy side effects. The ‘kapha’ helps the ‘visha’ to retain inside the body. In the Vedic system, cancer is viewed as a psychic disorder, a disruption in the aura allowing the entrance of a negative astral force. Emotional cleansing, mantra, and meditation are important to counter this. The Polyherbal preparations (Chavanprash avaleha, Triphala) show control on the side effects of chemotherapy and radiotherapy by showing the radio-protective effect. Here in this review, we have tried to demystify the Ayurveda principles and its role for the possible treatment of side effects of chemotherapy and radiotherapy with a view leading to enhanced quality of life for cancer patients. © 2020 iGlobal Research and Publishing Foundation. All rights reserved.
癌症是造成死亡的主要原因,每年在全球夺走约960万人的生命。用于癌症治疗的药物、化学疗法和放射疗法通常是有毒的,并且会损害邻近的健康细胞。副作用可能是急性的(在治疗后几周内发生),中期或晚期(在治疗后数月或数年发生)。目前可用于克服治疗副作用的“保护剂”尚未达到标准,因此需要寻找更有效的替代品。阿育吠陀是一种古老的医学体系,由于其无副作用的治疗原则而被广泛应用。根据阿育吠陀,有三个“dosha”(Vata, Pitta和Kapha)。化疗和放疗的副作用是非常常见的加重“皮塔多沙”的迹象。在阿育吠陀,两个“毗沙”(gara和dushivisha)也在那里。这些会引起化疗和放疗副作用等症状。“kapha”帮助“visha”保持在体内。在吠陀体系中,癌症被视为一种精神疾病,是气场的破坏,允许负面星体力量进入。情绪净化、咒语和冥想对对抗这种情况很重要。多草药制剂(Chavanprash avaleha, Triphala)通过显示放射保护作用来控制化疗和放疗的副作用。在这篇综述中,我们试图揭开阿育吠陀原理的神秘面纱,以及它在治疗化疗和放疗副作用方面的作用,以期提高癌症患者的生活质量。©2020全球研究与出版基金会。版权所有。
{"title":"Ayurveda in Management of Side Effects of Oncotherapy","authors":"S. Sarkar, Ananta Choudhury, B. Dey","doi":"10.35652/igjps.2021.113003","DOIUrl":"https://doi.org/10.35652/igjps.2021.113003","url":null,"abstract":"Cancer, being a leading cause of death takes away approximately 9.6 million life per year globally. Drugs, chemotherapy and radiation therapies used for cancer treatment are often toxic and damages the adjacent healthy cells. The side effects may be acute (occurring within a few weeks after therapy), intermediate or late (occurring months or years after the therapy). The presently available “protectors” for overcoming the side effects of therapy have not been up to the mark which creates the need of finding a more efficient alternative. Ayurveda an ancient system of medicine and most widely practiced especially because of its side effects free treatment principles. According to Ayurveda, there are three ‘doshas’ (Vata, Pitta, and Kapha). The side effects of chemotherapy and radiotherapy are very common with the signs of aggravated ‘pitta dosha’. In Ayurveda, two ‘vishas’ (gara and dushivisha) are also there. Theses cause symptoms like chemotherapy and radiotherapy side effects. The ‘kapha’ helps the ‘visha’ to retain inside the body. In the Vedic system, cancer is viewed as a psychic disorder, a disruption in the aura allowing the entrance of a negative astral force. Emotional cleansing, mantra, and meditation are important to counter this. The Polyherbal preparations (Chavanprash avaleha, Triphala) show control on the side effects of chemotherapy and radiotherapy by showing the radio-protective effect. Here in this review, we have tried to demystify the Ayurveda principles and its role for the possible treatment of side effects of chemotherapy and radiotherapy with a view leading to enhanced quality of life for cancer patients. © 2020 iGlobal Research and Publishing Foundation. All rights reserved.","PeriodicalId":13366,"journal":{"name":"Indo Global Journal of Pharmaceutical Sciences","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88559511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A Study on Media Optimization, Characterization and Purification of L-Asparaginase Producing Streptomyces sp. FSOF Strain Isolated from the Bay of Bengal Coastal Line 产l -天冬酰胺酶链霉菌(Streptomyces sp. FSOF)菌株的培养基优化、表征及纯化研究
Pub Date : 2021-01-01 DOI: 10.35652/igjps.2021.113005
Tejaswini Avn, Ramesh Malothu
The vast marine biodiversity provides abundant opportunities for the isolation and characterization of Streptomyces species with therapeutic applications. The present study is focused on isolation, characterization, media optimization of Streptomyces sp. FSOF strain for production and purification of L-Asparaginase at an economic level. Methods: The isolated strain from the intertidal region of Bay of Bengal coastal region is characterized by physicochemical, genotypic and by phylogenetic methods. The growth medium of Streptomyces FSOF strain is optimized for high enzyme activity and further purified by Ion exchange chromatography. Results and Conclusion: The FSOF isolate exhibited 4.3 IU/ml enzyme activity in m9 broth. The enzyme activity of the FSOF strain is further analyzed in various growth mediums where 5.9 IU/ml activity is observed in tryptic soy broth. The purified L-asparaginase from FSOF isolate exhibited 23.33 IU/mg specific activity with 3.12 fold purification. The 16s rRNA sequence of FSOF isolate is found to have 99.88% similarity with Streptomyces albidoflavius and Streptomyces odorifer strains. The sequence is further deposited in GenBank (accession number MN562193.1) for future analysis. © 2020 iGlobal Research and Publishing Foundation. All rights reserved.
广阔的海洋生物多样性为具有治疗应用价值的链霉菌的分离和鉴定提供了丰富的机会。本文主要研究了链霉菌fsofs菌株的分离、鉴定、培养基优化,以期在经济水平上生产和纯化l -天冬酰胺酶。方法:对从孟加拉湾沿岸潮间带分离的菌株进行理化、基因型和系统发育鉴定。对链霉菌FSOF菌株的生长培养基进行了优化,并对其进行了离子交换层析纯化。结果与结论:菌株在m9肉汤中酶活性为4.3 IU/ml。进一步分析了FSOF菌株在不同培养基中的酶活性,其中在胰蛋白酶豆汤中的酶活性为5.9 IU/ml。纯化得到的l -天冬酰胺酶比活性为23.33 IU/mg,纯化倍数为3.12倍。FSOF分离物的16s rRNA序列与白黄链霉菌和臭臭链霉菌具有99.88%的相似性。该序列进一步存入GenBank(登录号MN562193.1)以供将来分析。©2020全球研究与出版基金会。版权所有。
{"title":"A Study on Media Optimization, Characterization and Purification of L-Asparaginase Producing Streptomyces sp. FSOF Strain Isolated from the Bay of Bengal Coastal Line","authors":"Tejaswini Avn, Ramesh Malothu","doi":"10.35652/igjps.2021.113005","DOIUrl":"https://doi.org/10.35652/igjps.2021.113005","url":null,"abstract":"The vast marine biodiversity provides abundant opportunities for the isolation and characterization of Streptomyces species with therapeutic applications. The present study is focused on isolation, characterization, media optimization of Streptomyces sp. FSOF strain for production and purification of L-Asparaginase at an economic level. Methods: The isolated strain from the intertidal region of Bay of Bengal coastal region is characterized by physicochemical, genotypic and by phylogenetic methods. The growth medium of Streptomyces FSOF strain is optimized for high enzyme activity and further purified by Ion exchange chromatography. Results and Conclusion: The FSOF isolate exhibited 4.3 IU/ml enzyme activity in m9 broth. The enzyme activity of the FSOF strain is further analyzed in various growth mediums where 5.9 IU/ml activity is observed in tryptic soy broth. The purified L-asparaginase from FSOF isolate exhibited 23.33 IU/mg specific activity with 3.12 fold purification. The 16s rRNA sequence of FSOF isolate is found to have 99.88% similarity with Streptomyces albidoflavius and Streptomyces odorifer strains. The sequence is further deposited in GenBank (accession number MN562193.1) for future analysis. © 2020 iGlobal Research and Publishing Foundation. All rights reserved.","PeriodicalId":13366,"journal":{"name":"Indo Global Journal of Pharmaceutical Sciences","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82536351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Indo Global Journal of Pharmaceutical Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1